Loading
A phase 1/2 trial of [203Pb]VMT-α-NET in neuroendocrine tumours, pancreatic ductal adenocarcinoma and pheochromocytoma and paraganglioma, run by Perspective Therapeutics, now recruiting.
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors is a phase 1/2 interventional study registered as NCT05636618 by Perspective Therapeutics, with 300 participants planned, started 2023-09-27 and due to reach its primary completion in 2029-11-26. Interventions recorded: [203Pb]VMT-α-NET and [212Pb]VMT-α-NET.
Shares Perspective Therapeutics, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pheochromocytoma and paraganglioma (PPGL) and the tag pipeline.
Shares Pheochromocytoma and paraganglioma (PPGL) and the tag pipeline.
Shares Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.